Agglomerated carbon black nanoparticles (CBNPs) administered via respiratory or subcutaneous routes have been shown to promote allergic sensitization to coadministered ovalbumin (OVA) protein in rodents. In the present study, we aimed to model and elucidate the mechanism of this adjuvanticity using an in vitro assay based on T cell sensitization to ovalbumin 323-339 peptide (OVA p ). CBNP base particles of 22 and 39 nm were characterized and termed CBNP22 and CBNP39 powders. Splenic leukocytes derived from transgenic DO11.10 mice were exposed to suspensions of media alone, concanavalin A mitogen, CBNP agglomerates smaller than 220 nm, OVA p alone, OVA p + anti-CD28 costimulant, OVA p + cyclosporin A immunosuppressant, or OVA p + CBNPs. Samples were analyzed at 72 h post-exposure. Proliferation rate, a marker of cellular mitosis, was assessed. Polymerase chain reaction arrays were used to assess genes involved in allergic response pathways. The mitogen control, costimulatory control, and immunosuppressive control chemicals modified the T helper cell proliferation rate. CBNP22 mildly reduced proliferation at 12 g/ml, but CBNP39 did not. Gene expression analysis of cells treated with OVA p showed that coincubation with 12 g/ml CBNP22 enhanced gene expression of interleukin-4 (IL-4), IL-10, and IL-13, all allergyassociated Th2 cytokines. Coincubation of OVA p with 12 g/ml CBNP39 significantly enhanced IL-13 gene expression concurrent with downregulation of the Th1-associated transcription factor Stat4. IL-4 and IL-13 protein secretion reflected the mRNA trends. The changes were consistently higher in cells exposed to CBNP22 than CBNP39, suggesting that smaller particle size, higher surface area, and higher purity were associated with the direct adjuvant effect on Th2 cells in this genetically susceptible model of OVA allergy.
Allergy results from the mistaken recognition of an environmental protein by leukocytes (Waserman and Watson, 2011) . Immunoglobulin E (IgE)-mediated mechanisms are the most common. Initial sensitization involves presentation of the allergenic protein by antigen-presenting cells and recognition by T cells in a cytokine microenvironment that promotes allergy pathways. T cells activated in such a microenvironment secrete cytokines such as IL-4 and IL-13, which act in an autocrine manner to promote differentiation to a Th2 phenotype, and act in a paracrine manner to promote B-cell maturation and IgE antibody production (Hunig et al., 2010; Yagi et al., 2011) . The exogenous adjuvants that influence the switch from tolerance to sensitization remain largely uncharacterized (Jenerowicz et al., 2012) .
Engineered nanomaterials have an internal or external surface structure dimension between 1 and 100 nm and can exhibit unique physical, chemical, and biological characteristics associated with their nanostructure. These chemicals are increasingly used in consumer products. Therapeutic uses take advantage of immunostimulatory or immunosuppressive properties. For example, in vaccine development the elicitation of an inflammatory reaction may be advantageous by conferring immune potentiation to the coadministered vaccine (Fahmy et al., 2008) . Humans may be exposed incidentally or occupationally to engineered nanomaterials, and early studies have raised concerns about safety to humans and the environment (Bonner, 2010; Johnston et al., 2013) .
Using wild-type animal models, a number of studies have demonstrated an association between exposure to nanomaterials and enhanced allergic reactions, as reviewed by Hussain et al. (2012) . This outcome appears to depend on physiochemical characteristics and dose. For example, respiratory exposure to ultrafine particulate air pollutants can potentiate immune responses to concomitantly exposed antigens such as pollen (Chang, 2010) . Single and multi-walled carbon nanotubes increased lung inflammation and allergen-specific IgE levels in mice sensitized to ovalbumin (OVA) egg allergen (Nygaard et al., 2009) . On the other hand, nano-sized silver particles diminished allergic airway reactions in mice sensitized to OVA (Park et al., 2010) . Thus, high-throughput studies involving well-characterized nanomaterials are required to determine the C Crown copyright 2014 ADJUVANTICITY OF NANOPARTICLES IN VITRO 323 primary target tissues and mechanisms in order to understand if nanomaterials pose a risk to humans.
Carbon black (CB) is a carbonaceous material produced by incomplete combustion of petroleum products. Bulk-sized CB is mainly used as a reinforcing agent for rubber and is also used in printing inks, plastics, and food contact products. Micron-sized bulk CB particles did not modify allergic airway sensitization in wild-type mice, whereas nano-sized carbon black nanoparticles (CBNPs) promoted this adverse reaction (de Haar et al., 2006; Nygaard et al., 2009 ). However, it was unclear if this was a direct effect of the CBNPs on immune cells or a secondary effect from toxicity to other tissues. In vitro assays can answer these mechanistic questions (Pfaller et al., 2010) .
DO11.10 mice are transgenic for a T cell receptor that reacts to OVA 323-339 peptide (OVA p ) and develop allergy symptoms similar to humans (Okamoto et al., 2005) . We previously used primary splenic leukocytes from DO11.10 mice to determine the effect of exogenously applied factors on the mechanisms of T cell activation (Chakir et al., 2003) . In the present study, we employed this in vitro model to determine if CBNPs modulate allergic sensitization to OVA p by direct modulation of Th1 and Th2 cytokine pathways.
MATERIALS AND METHODS

Materials.
Printex 90 CB nanomaterial powder from Evonik/Degussa (Frankfurt, Germany) was a kind gift from Dr. Håkan Wallin of the National Research Center for the Working Environment, Denmark, and was termed CBNP22 because the primary particles were a mean of 22 nm. Carbon nanopowder (Sigma-Aldrich, St. Louis, MO) was termed CBNP39 because the primary particles were 39 nm. Standard safety precautions were used (Howard, 2012) . Fetal bovine serum was from HyClone Laboratories (Logan, UT). RPMI 1640 medium, penicillin, streptomycin, L-glutamine, and ␤-mercaptoethanol were from Invitrogen (Burlington, ON, Canada).
Surface area and pore volume of CBNP powders. Nanomaterial characterization was carried out at Intertek ASA (Allentown, PA). Surface area and pore volume were characterized by Brunauer Emmett Teller analysis (Nygaard et al., 2009) . Briefly, nitrogen adsorption isotherms were measured on a Micromeritics ASAP unit to a relative pressure of 1.0 at 77 K. Samples were activated by degassing in stages up to 300
• C under dynamic vacuum. Temperatures were ramped at ∼10
• C/min to preset temperatures and held until a vacuum pressure of 10 −3 torr was achieved. The activation procedure used temperatures of 80
• C, 100
• C, and 300
• C. The samples were held at 300
• C until a vacuum of ∼10 −4 torr was obtained. Cumulative pore volume was quantified assuming applicability of the Kelvin equation and a thickness curve represented by the Harkins and Jura model.
Composition of CBNP powders.
The elemental composition was analyzed on a PANalytical PW4400R Axios wavelength dispersive X-ray fluorescence spectrometer in a helium atmosphere. A carbon matrix correction was applied and elemental concentrations were calculated as the weight percentage of each oxide, normalized to 100% using the program UNIQUANT. Elements representing greater than 0.1 weight percentage were reported.
Surface composition and functionality of CBNP powders. X-ray photoelectron spectroscopy was performed on a PHI 5000VersaProbe Spectrometer equipped with multiple channel plates and a focused Al monochromatic X-ray source. Briefly, high-resolution multiplex scans were performed at 23.50 eV pass energy, 0.100 eV/step, and a 100 ms/step dwell time. CasaXPS software used a transmission function corrected Area Sensitivity Factor. The atomic percentage of surface elements was calculated, omitting hydrogen, and was normalized to 100%. Curve fitting for chemical functionality was charge corrected to C amorphous 283.7 eV and functionalization of the surface carbon was quantified.
CBNP primary particle and agglomerate size before and after sonication. Scanning electron microscopy was performed with the CBNP powders before and after suspension and sonication in ethanol. Images were obtained with a Hitachi S-4800 field emission electron microscope at 5 kV accelerating voltage and analysis was performed using AnalySIS software. The longest particle dimension was measured.
Zeta potential. Zeta charge potential analysis was performed with a Malvern ZetaSizer following sonication of the CBNPs in water at pH 7.1. A wavelength of 632 nm was used along with a relative refractive index of 1.50-0.10 and a liquid refractive index of 1.33 for water.
Suspension of CBNPs in cell culture medium. Fetal bovine serum was heat inactivated at 56
• C for 30 min. Complete RP-10 cell culture medium at pH 7.1 consisted of RPMI 1640, 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 g/ml streptomycin, 2 mM L-glutamine, and 25 M ␤-mercaptoethanol (Chakir et al., 2003) . Suspensions of the CBNP powders were prepared in this RP-10. A Q700 sonicator with a microtip probe (Qsonica, Newtown, CT) was used to sonicate for 15 effective min at 10% amplitude on ice, with 30 s of manual mixing by inversion every 5 min (Jacobsen et al., 2009 ). An aliquot was retained for a standard concentration curve, and the remainder was filtered with a 220 nm Steriflip (Millipore, Billerica, MA) to sterilize the suspension and purify agglomerates smaller than 220 nm-reflecting a defined size range from a specific processing condition (Bourdon et al., 2012a) .
Characterization of CBNPs in cell culture medium. The mass concentration of CBNPs in the Steriflip filtrate used for cell culture was quantified by spectrophotometry at 470 nm using a Powerwave XS plate reader and KC4 software (BioTek, Winooski, VT) against a standard curve of unfiltered CBNPs. The filtrates were then adjusted for final concentrations of 0.0125, 0.125, 1.25, and 12.5 g/ml and frozen at −80
• C until equilibration to 37
• C for cell exposure (Jacobsen et al., 2009 ). Nanomaterial surface area per volume was calculated as previously described (Pfaller et al., 2010) .
Endotoxin in the filtered CBNP suspensions was measured using the Limulus amebocyte lysate kinetic-QCL assay (Lonza, Allendale, NJ) as in Neun and Dobrovolskaia (2011) . Briefly, CBNP aliquots were centrifuged six times for 10 min at 18,000 × g to remove nanomaterials before quantification of free endotoxin (Nygaard et al., 2009) .
A similar approach was used to determine if the nanomaterials sequestered a significant amount of protein from the medium (de Haar et al., 2006) . Briefly, the RP-10 media and CBNP suspensions in RP-10 were centrifuged four times at 22
• C for 15 min at 8000 × g. Protein level in the supernatants was quantified using the BCA Protein Assay kit (Thermo Scientific, Rockford, IL).
Animal care. Animal handling complied with the guidelines of the Canadian Council on Animal Care, and protocols were approved by the Health Canada Animal Care Committee (Ottawa, ON). D011.10 mice were obtained from Jackson Laboratory (Bar Harbor, ME). Equal numbers of 7 week old male and female mice were pair housed and acclimated for 1 week with ad libitum access to Harlan 2014 diet and drinking water. These 8 week old mice were then anesthetized with isoflurane, cardiac puncture was performed, and the spleen was excised.
Preparation of primary splenic leukocytes. The spleen was placed in sterile RPMI medium at 4
• C and single cell suspensions were prepared as described previously (Chakir et al., 2003) . Briefly, segments of spleen were crushed between frosted glass slides and filtered through a 70 m nylon strainer. Erythrocytes were eliminated with Ack lysis buffer (Invitrogen). The remaining splenic leukocytes were washed in RPMI and counted by trypan blue exclusion.
OVA peptide and immunomodulatory control chemicals.
OVA 323-339 peptide (Anaspec, Fremont, CA) was resuspended in RP-10 and sterile filtered with a prerinsed Millex-GP filter (Millipore). A pilot study determined that DO11.10 splenic leukocytes treated with 0.4M OVA p had a half-maximal proliferation and cytokine response (data not shown). Thus, a final culture concentration of 0.4 M OVA p was used. Purified NA/LE hamster antimouse CD28 antibody (clone 37.51, BD Pharmingen) was used at 10 g/ml (Blankson and Morse, 1994) . Solid cyclosporin A from Tolypocladium inflatum (Sigma) was resuspended in dimethyl sulfoxide, sterilized with a Millex-LG syringe filter (Millipore), and diluted 1/10,000 to a final culture concentration of 1 g/ml (Shimoda et al., 1998) . Aseptically processed concanavalin A (Con A) Type IV-S (Sigma) was used in RP-10 at 2 g/ml.
Flow cytometry phenotyping and proliferation assay. On day 0, splenic leukocytes were stained with 5 M CellTrace Violet (Invitrogen) and 1 × 10 6 stained cells were cultured in 1 ml RP-10 in a 24-well plate (BD Falcon, Mississauga, ON) with or without control chemicals at 37
• C in a humidified atmosphere and 5% CO 2 in air. At 72 h the nonadherent cells were harvested, washed, and stained with V500 anti-mouse CD45, PE anti-mouse KJ1-26 T cell receptor, and APC anti-mouse CD4 (BD). Cells were fixed with formalin and cell surface phenotype was analyzed on an LSR Fortessa flow cytometer with FacsDiva software (BD). Briefly, after gating on CD45 + leukocytes, the percentage of OVA p -specific KJ1-26 + CD4 + T helper cells among that population was determined. The percentage of cells that proliferated was also assessed with ModFit LT, version 3.2 (Verity Software House, Topsham, ME). Briefly, gated leukocytes were further gated on KJ1-26 + CD4 + cells to generate a CellTrace Violet histogram for that population. The parent generation and spacing of the daughter generations in the histograms was set on the cells treated with OVA p . The percentage of cells in daughter generations was quantified. Cells from individual mice were excluded from the analysis if the proliferation of the OVA p -treated cells was within one standard deviation (SD) of the mean proliferation of the OVA p + anti-CD28 group or within one SD of the mean of the OVA p + cyclosporin A group.
To rule out nanomaterial interference, wells of cells that had not been treated were spiked with CBNP, before harvesting at 72 h, to ensure that the nanomaterials did not interfere with antibody binding or fluorescence compared with nonspiked cells.
Real-time qPCR array plate analysis. Nonstained splenic leukocytes were treated for 72 h as described above, harvested, washed with PBS, and stored at −70
• C. Total RNA was isolated using an miRNeasy Mini kit (Qiagen, Toronto, ON). cDNA was synthesized using an RT 2 First Strand kit (Qiagen). Briefly, 500 ng of total RNA was treated with genomic DNA elimination mix. Reverse transcription was carried out for 15 min at 42
• C followed by 5 min at 95 • C. RT 2 profiler polymerase chain reaction (PCR) array plates for mouse Th1-Th2-Th3 (SA Biosciences, Mississauga, ON) were used on a ViiA7 real-time PCR system (Applied Biosystems, Burligton, ON). One 10 min cycle at 95
• C was followed by 40 cycles consisting of 15 s at 95
• C and 1 min at 60 • C. Threshold cycle (Ct) values were determined for each gene following the establishment of an automated baseline and a defined threshold. Targets IL23a, IL17a, Ccl11, Ccl7, Ccr10, IL12b, IL1r1, IL7 , and Sftpd were excluded because their melting curve peak had high SD between plates, indicating non-specific PCR priming. The remaining 75 genes were analyzed using the SA Biosciences RT 2 Profiler PCR Array Data Analysis Template v3.3 by a comparative Ct method (Lewkowicz et al., 2011) . Gusb, Hprt, and Hsp90ab1 were se-lected by the RT 2 software as the reference housekeeping genes. The 2 -Ct values were used to calculate fold change for each treatment group relative to the OVA p control group. A foldchange cut-off of ≥4 or ≤0.25, along with a significant difference p < 0.05 from the OVA p control group, was used specifically for this model because it reproducibly flagged CBNP concentrations at which mRNA gene expression changes corresponded with significant protein changes-a key functional indicator of effects. The GeneBank Refseq for the genes with changes which met the cut-off requirements are NM 021283 for IL-4, NM 010548 for IL-10, NM 008355 for IL-13, and NM 011487 for Stat4. A clustergram analysis was performed using the RT 2 software (Lu et al., 2011) .
Quantification of intracellular and secreted proteins. Nonstained splenic leukocytes were treated for 72 h as described above. The cells were used for Western blot quantification of intracellular STAT4. Cell-free culture supernatants were also used for analysis of secreted proteins following centrifugation at 12,000 × g for 10 min at 4
• C to remove particles. IL-4 was quantified with an OptEIA enzyme-linked immunosorbent assay (ELISA) kit as well as a Cytometric Bead Array kit for mouse Th1/Th2 cytokines (Goulaouic et al., 2008; Val et al., 2009) . IL-10 and IL-13 were assessed with Flex Set kits (BD). False positives from nanomaterial interference were ruled out before culture by analyzing media compared with CBNP suspensions. False negatives were ruled out by comparing nonspiked and CBNP-spiked cytokine standard (Neun and Dobrovolskaia, 2011) .
Intracellular STAT4 was also quantified in situ by cell-based ELISA. Briefly, on day 0, 96-well culture plates were precoated with 10 g/ml poly-L-lysine (Sigma) for 30 min at 37
• C, washed with sterile water, and dried. Cells were cultured in triplicate at 1 × 10 5 /well in 200 l and treated as above. At 72 h, supernatants were harvested and the cells were fixed with 8% formaldehyde in PBS for 20 min at 22
• C. Intracellular STAT4 was quantified by Fast Activated Cell-based ELISA for nonadherent cells (Active Motif, Carlsbad, CA). To ensure that residual nanomaterials did not interfere with the assay, control wells containing CBNPs were developed without the primary antibody.
Statistical analysis. All statistical analyses were performed with SigmaPlot version 12.0. A Shapiro-Wilk normality test and an equal variance test were performed, followed by one-way analysis of variance (ANOVA) (Rieu and Powers, 2009 ). The parametric Holm-Sidak post hoc test was run versus the control. For nonparametric data, the Kruskal-Wallis one-way ANOVA on Ranks was run and followed by the Dunnett's post hoc test versus the control if treatment group sizes were equal or followed by the Dunn's post hoc test versus the control if treatment group sizes were unequal. 
RESULTS
Particle Characterization
The surface area and total pore volume of the CBNP22 powder were approximately six and four times greater than the CBNP39 powder, respectively (Table 1) . The CBNP22 was composed of 99.77% carbon, containing sulfur as the greatest contaminant. CBNP39 was less pure consisting of 83.06% carbon containing the notable contaminants silicon, zinc, and sulfur ( Table 2 ). The surface of the CBNP22 particles was 98.4 ± 0.1 relative atomic percent carbon with the remainder oxygen. Carbon represented 93.8 ± 0.4% of the CBNP39 surface. The remainder was 4.7 ± 0.5% oxygen, 0.6 ± 0.1% silicon, 0.6 ± 0.1% sulfur, and 0.5 ± 0.1% zinc, the latter three present as silicate and zinc sulfide. The functionalization of the surface carbon of both materials was predominantly amorphous (Table 3) .
Particle shape and size was characterized before and after sonication. The CBNP22 and CBNP39 powders were highly agglomerated (Table 4) . Following suspension in ethanol, sonication, and drying, the primary nanoparticles making up the powders were visible as distinct primary structures on the agglomerate surface (Fig. 1) . Sonication reduced the mean size and size distribution of these amorphous primary particles (Table 4 ). The CBNP22 primary particles were a mean of 22 nm and those making up CBNP39 were 39 nm. Peak zeta surface charge was −31.0 mV for CBNP22 and −31.1 mV for CBNP39.
For cell culture, the CBNPs were dispersed by sonication in complete cell culture medium and sterilized by filtration through a 220 nm filter to purify this size range. Mass per volume concentration in the filtrate was quantified and normalized. At the highest dose of 12 g/ml CBNP22, the particle surface area per volume was 0.0041 m 2 /ml. The same concentration of CBNP39 was 0.0006 m 2 /ml. The nanomaterials did not significantly alter the concentration of free protein in the cell culture medium. Free endotoxin level was less than 0.005 EU/ml, or less than 0.4 EU/mg nanomaterial, and it was less than 0.005 EU/mg OVA p ; well below immunomodulatory concentrations. Notes. Data represent mean ± standard error of two separate scans by wavelength dispersive X-ray fluorescence spectrometry. bl denotes below the selected inclusion limit of 0.1 weight percent.
TABLE 3 Surface Chemical Functionality of the Carbon Nanomaterial Powders
Surface functionality CBNP22 (atomic%) CBNP39 (atomic%) C amorphous 283.7 C1s 64.9 ± 0.8 71.6 ± 1.3 CH x 285.5 C1s 9.8 ± 0.6 6.9 ± 0.4 C-O 287.1 C1s 7.0 ± 0.6 3.8 ± 2.4 O-C-O 288.2 C1s 5.7 ± 0.0 4.8 ± 0.0 O-C = O 289.5 C1s 6.7 ± 0.8 4.5 ± 0.1 CO 3 291.2 C1s 4.6 ± 1.0 3.0 ± 0.1
Note. Data represent mean ± SD of X-ray photoelectron spectroscopy measurements made at two sample locations. 
Effects on T Cell Proliferation and Phenotype
Following 72 h culture in media alone, the percentage of OVA p -specific T helper cells that completed mitosis was 23.4 ± 4.9% ( Figs. 2A and B) . The Con A positive control promoted significant T cell proliferation. In cells cultured with the filtered CBNPs alone there was a statistically significant suppression of cellular division at the highest dose of CBNP22, which was a relatively small fold-change from the media control (Fig. 2B) . CBNP39 had no effect on proliferation. An MTT metabolic assay demonstrated that the nanomaterials did not reduce cell viability (data not shown). Culture of the splenic leukocytes with OVA p resulted in a cell division level of 62.6 ± 9.9% ( Figs. 2A  and C) . The T cell-specific anti-CD28 agonist enhanced proliferation to OVA p . The cyclosporin A immunosuppressant inhibited the response. Coculture of the cells with OVA p in combination with the carbon nanomaterial suspensions did not alter the proliferative response in comparison to OVA p alone (Fig. 2C) . Flow cytometric phenotyping confirmed that the final percentage of KJ1-26 + CD4 + T helper cells at 72 h corresponded with the proliferation rate (data not shown).
Effects on T Cell Cytokine Pathways
Upregulation of cytokines can occur in the absence of changes in T cell proliferation (Rojo et al., 1989) . Thus, we selected a Th1-Th2-Th3 PCR array to screen for effects on a panel of 84 genes consisting of transcription factors, cytokines, and chemokines. As described below, cytokine and chemokine secretion was very low in cells treated with CBNPs alone. Thus, we focused the gene expression analysis screening on the OVA p treatment groups to identify genes of interest for further protein analysis (Fig. 3) . Among the studied genes, there was a significant increase in gene expression of the Th2 cytokines IL-4, IL-10, and IL-13 above the fold-change threshold in the cells treated with OVA p in combination with the highest dose of CBNP22, compared with OVA p alone (Table 5) . IL-13 transcript was also upregulated in the cells treated with OVA p in combination with the highest dose of CBNP39. Expression of the Stat4 transcription factor, which is downregulated during differentiation of Th2 cells, was significantly reduced following coincubation with OVA p and 12 g/ml CBNP39. Although only these four genes met the cut-off criteria, the clustergram revealed dose-dependent trends in other functionally related genes, which provides useful subclinical mechanistic data (Fig.  3) . With regard to CBNP dose, the cut-off was not surpassed for any genes at or below the nanomaterial dose of 1.2 g/ml.
In order to determine if transcriptional changes translated to significant changes at the protein level, intracellular STAT4 was measured by cell-based ELISA. The protein showed a 25% reduction at the highest concentration of CBNP39 during the response to OVA p (data not shown). However, there were no statistically significant differences, as confirmed by Western blotting (data not shown). Secreted cytokine proteins were also quantified. The splenic leukocytes cultured in media without antigenic stimulation secreted low baseline levels of IL-4, IL-10, and IL-13 (Fig. 4) and the filtered carbon suspensions alone did not induce these cytokines. Anti-CD28 significantly enhanced the OVA p -induced production of these Th2 cytokines, and cyclosporin A was inhibitory. Culturing the cells with OVA p combined with 12 g/ml CBNP22 significantly enhanced IL-4 and IL-13 protein levels compared with cells treated with OVA p alone. Similar, but nonsignificant trends were observed following coincubation of CBNP39.
DISCUSSION
The present work used an in vitro assay with cells from transgenic DO11.10 mice to mechanistically determine the threshold concentration of nanomaterials that directly modulate sensitization to OVA protein from chicken egg white. To validate the approach, we demonstrated that Con A, a T cell mitogen, enhanced proliferation of OVA-specific T cells as well as the secretion of IL-10 and IL-13. Furthermore, signaling through the CD28 costimulatory receptor on activated T cells synergized with the OVA p -specific T cell receptor to enhance proliferation as well as IL-4, IL-10, and IL-13, consistent with previous reports (Blankson and Morse, 1994; Hunig et al., 2010; Suntharalingam et al., 2006) . Lastly, cyclosporin A, an immunosuppressant to T cells (Shimoda et al., 1998) , reduced the proliferative response to OVA p and suppressed cytokine production.
In this work, two carbon-based model nanomaterial powders were characterized. Comparably, a previous study with sonicated 14 nm Printex 90, termed CBNP22 in the present study, confirmed that nonfiltered Printex 90 was agglomerated in suspension (Bourdon et al., 2012b) . Dynamic light scattering hydrodynamic volume-size distribution analysis showed a peak size of 3100 nm. In the present study, the sonicated, nonfiltered CBNP22 showed agglomerates with a mean diameter of 3900 nm consisting of primary particles with a diameter of 22 nm. CBNP39 agglomerates were a mean of 7200 nm and consisted of 39 nm base particles. The CBNP22 surface charge was similar to previous reports (Bourdon et al., 2012b) . Bourdon et al. (2012b) used filtration to confirm the presence of free Printex 90 nanoparticles as small as ∼7 nm in a saline suspension containing 10% bronchoalveolar lavage fluid. Another report demonstrated that Printex 90 in 2% fetal bovine solution maintained particle size peaks at 98 and 153 nm, indicating small agglomerates (Jacobsen et al., 2008) . To study this size range, we used a CBNP suspension filtrate of ≤220 nm for cell exposure.
To determine if the mechanism by which CBNPs promote allergy to OVA involves direct effects on immune cells, the DO11.10 mouse splenic leukocytes were treated for 3 days in culture. The CBNPs alone did not induce proliferation or cytokine secretion. Coincubation of the CBNPs with OVA p did not alter T cell proliferation to OVA p , however, CBNP22 at 12 g/ml significantly increased IL-4 and IL-13, indicating that Notes. Data represent the mean ± SD of PCR fold-change values relative to the ovalbumin 323-339 peptide (OVA p ) group for cells from n = 3 mice. The table displays the 4 out of 84 genes for which a treatment group showed a fold change ≥4 or fold change ≤0.25, along with a significant difference p < 0.05 compared with the OVA p alone group. a indicates the groups that met these criteria.
the nanomaterials modified cytokine production during sensitization. These cytokines act in common in an autocrine manner on the IL-4 receptor-␣ signaling pathway to promote naïve T helper cell differentiation to a Th2 phenotype, driving the mechanism of allergic sensitization (Chakir et al., 2003; Hunig et al., 2010; Paul and Zhu, 2010) . They also promote B-cell activation and IgE antibody production. Thus, modulation of these cytokines is a mechanism by which agglomerated CBNPs act as an adjuvant to promote subcutaneous and respiratory allergy (Nygaard et al., 2004 (Nygaard et al., , 2009 .
In comparison with the present study, the in vivo effect of CBNPs on the proliferation and cytokine production of adoptively transferred DO11.10 mouse OVA-specific CD4 T cells in the lung of recipient Balb/c mice was previously studied (de 2, or (h) 12 ug/ml filtered CBNP39. Th1-Th2-Th3 PCR plate analysis was performed. The heat map reflects the average relative expression between treatment groups for cells from n = 3 mice. The 75 genes that met the inclusion criteria are displayed, and the dendogram grouped genes that had similar expression trends across treatment groups. Haar et al., 2008) . CBNPs were applied intranasally on days 1, 2, and 3. On day 5, cells were sampled from the lungs. The CBNPs alone did not modify T cell proliferation. However, in mice that received these nanomaterials in combination with OVA, cell proliferation was increased compared with OVA. Airway inflammation was also increased. Cells from the peribronchial lymph nodes that drain the lungs were re-stimulated in culture for 4 days, and the cells from the mice that had received OVA with CBNP secreted significantly higher levels of IL-4, IL-5, IL-10, IL-13, and IFN-␥ than cells from mice treated with OVA (de Haar et al., 2008) . This cytokine profile is similar to that observed in the present study.
CBNP22 had substantially lower levels of immunomodulatory silicate, zinc sulfide, and other impurities than CBNP39, and thus higher carbon content. It also had higher surface area as a result of its smaller particle size and higher pore volume. Together, these properties were associated with a more pronounced effect on cytokine protein production than CBNP39. Similarly, an in vivo study with standard Balb/c mice found that 14 nm Printex 90 had a greater effect on OVA allergen-induced airway inflammation and peribronchial lymph node cell production of IL-4, IL-5, IL-10, IL-13, and IFN-␥ than the same mass dose of 260 nm Huber 990 (de Haar et al., 2006) . Likewise in ICR mice, 6 week exposure once per week to 14 nm Printex 90 had a greater effect on lung antigen-presenting cells than 56 nm Printex 25 (Koike et al., 2008) . These in vivo studies did not determine if this was a direct effect on immune cells or secondary from toxicity to other tissues.
Adjuvanticity mechanisms for particulate material can include adsorption of allergens resulting in protection from degradation, increased delivery of adsorbed allergens to phagocytic antigen-presenting cells, and nonspecific modulation of the immune system through mechanisms such as oxidative stress (Hussain et al., 2012) . Printex 90 has been demonstrated to induce reactive oxygen species and maturation of mouse dendritic cells at an in vitro concentration of 5 g/ml (Jacobsen et al., 2008; Koike et al., 2008) . Similar effects were observed with 30-50 nm CB (de Haar et al., 2008) . We elucidated that CBNPs also enhanced sensitization to OVA p by direct induction of Th2 cytokine production during the cellular immune response to this protein. Thus, the immune system is a primary target tissue at high concentrations.
Although the present study demonstrates that high concentrations of CBNPs can promote allergic sensitization, this cannot be generalized to other nanomaterials, as immune effects are dependent on the unique physico-chemical structure and properties of each type of nanomaterial. For example, carbon-based fullerene structures have been shown to act as an antioxidant and inhibit mast cell-mediated allergic responses (Ryan et al., 2007) . High-throughput methodologies are useful for screening nanomaterials to identify potential risks.
Cell culture can provide a useful reflection of leukocytes in the apical fluids lining mucosal tissues. In the present study, exposure to 12 g/ml CBNPs was the threshold concentration that had an adverse effect by enhancing allergy-associated Th2 cytokines during exposure to OVA p . This mass concentration was present in 1 ml and represented 12 g total. There were no observed effects at the 1.2 g/ml concentration or below. Cell culture conditions may also approximate tissue exposure to a localized injection. Nygaard et al. (2009) sensitized mice with a single subcutaneous injection of OVA alone or OVA plus Printex 90 CBNPs. Following an OVA booster challenge, they quantified serum IgE antibodies specific for this protein. The lowest Printex 90 dose that significantly increased OVA-specific IgE was 50 g delivered in a 20 l volume. There were no observed adverse effects from the 12 g dose. Thus, the lack of adjuvanticity from 1.2 g/ml Printex 90 in the present assay is consis- tent with a subcutaneous NOAEL of 12 g for that endpoint in wild-type mice (Nygaard et al., 2009) .
The present work demonstrated that 12 g/ml CBNPs directly enhanced T helper 2 allergy pathways in OVA-specific leukocytes responding to their cognate antigen, which corresponded with in vivo adjuvanticity in wild-type mice at a comparable dose. Further work will be required to determine the effects of other categories of nanomaterials.
